PlainBillCongress, translated.Legislation. Context. Public interest.Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Congressional Research Service
Version 36 · Passed House amended · Jun 3, 2013
Safeguarding America's Pharmaceuticals Act of 2013 - (Sec. 2) Amends the Federal Food, Drug, and Cosmetic Act to establish requirements to facilitate the tracing of drug products through the pharmaceutical supply distribution chain.
Requires the Secretary of Health and Human Services (HHS) to establish standards for the exchange of transaction information.
Requires the Secretary to establish processes to: (1) provide waivers of requirements for undue economic hardship or emergency medical reasons; (2) provide waivers of requirements relating to product identifiers for prescription drug products packaged without sufficient space to bear the information; and (3) determine other prescription drug products or transactions that should be exempt from the requirements of this Act.
Showing the opening paragraphs of the official summary.
Establishes requirements for drug manufacturers, wholesalers, dispensers, and repackagers to ensure that all prior transaction information is provided at each transfer of ownership. Requires such entities to maintain such transaction information for three years. Sets forth exceptions, including for dispensing to a patient and returns.
Requires a manufacturer, wholesale distributor, dispenser, repackager, in the event of a recall or for the purpose of investigating a suspect prescription drug product or an illegitimate prescription drug product, to provide within two business days the applicable transaction documentation upon request by the Secretary or other appropriate federal or state official.
Requires a manufacturer or repackager to affix or imprint a prescription drug product identifier on each package and homogenous case of a prescription drug product.
Requires a manufacturer, wholesale distributor, dispenser, repackager, or third party logistics provider to ensure that each of its trading partners is authorized.
Requires a manufacturer, wholesale distributor, dispenser, repackager, and third party logistics provider to implement systems to: (1) investigate suspected illegitimate prescription drug products or, for a third party logistics provider, notify the owner of a need for such an investigation, and (2) handle illegitimate prescription drug products, including through quarantine, disposal, and appropriate notice to the Secretary and, as necessary, trading partners.
Requires manufacturers, wholesale distributors, repackagers to verify returned products before further distribution.
(Sec. 3) Requires the Secretary to establish projects and hold public meetings to enhance the safety and security of the pharmaceutical distribution supply chain.
Directs the Comptroller General (GAO) to examine implementation of the requirements established under this Act in order to inform regulations promulgated to enhance distribution supply chain safety and security.
Directs the Secretary to contract with a private, independent consulting firm with relevant expertise to conduct a technology and software study on the feasibility of dispensers that have 25 or fewer full-time employees conducting interoperable, electronic tracing of prescription drug products at the package level. Requires the Secretary to issue additional proposed regulations in 2027 to prevent a suspect, illegitimate or counterfeit product, or a product otherwise unfit for distribution from entering into or being further distributed in the supply chain.
(Sec. 4) Requires the Secretary to establish standards for the licensing of wholesale distributors and third party logistics providers. Requires third party logistics providers to be licensed by the state from which the drug is distributed or by the Secretary.
(Sec. 6) Applies specified criminal and civil penalties to violations of standards prescribed under this Act, including a certain enhanced penalty for knowing unlicensed activities, and failure to bear a prescription drug product identifier required by this Act.
(Sec. 7) Preempts state and local requirements related to tracing drugs through the distribution system, and licensure of wholesale distributors or third party logistics provider licensure.
(Sec. 8) Allows certain prescription drug labeling to be provided solely by electronic means.
People & committees
Rep. Latta, Robert E. [R-OH-5] · R–OH
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H2969-2978)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H2969-2978)
DEBATE - The House proceeded with forty minutes of debate on H.R. 1919.
Considered under suspension of the rules. (consideration: CR H2968-2984)
Mr. Latta moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 65.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 113-93.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 113-93.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We currently store references to these documents.
Source last updated: Apr 21, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1919 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1919 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1919 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1919 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.